Back
Day Range
$27.11
$27.97
52-Week Range
$8.73
$30.33
Volume
3,062,784
50D / 200D Avg
$25.80
/
$18.18
Prev Close
$26.87
Quick Summary
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -113.9 | 0.4 |
| P/B | 4.2 | 2.9 |
| ROE % | -3.2 | 3.9 |
| Net Margin % | -592.0 | 3.8 |
| Rev Growth 5Y % | 5.1 | 10.0 |
| D/E | 0.0 | 0.2 |
Analyst Price Target
Hold
$31.50
+15.1%
Low: $30.00
High: $34.00
Forward EPS
-$1.12
Est. Revenue
9.39M
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$1.09
-$0.13 – $5.07
|
2.99B | 2 |
| FY2029 |
$0.28
-$0.03 – $1.29
|
1.74B | 4 |
| FY2028 |
-$1.00
-$1.48 – -$0.20
|
513.21M | 7 |
No quarterly estimates available
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 13, 2026 |
QVT Financial LP
|
sell | 375,784 | $26.49 | $9,956,768.16 |
| Feb 12, 2026 |
QVT Financial LP
|
sell | 425,000 | $26.72 | $11,367,000.00 |
| Feb 11, 2026 |
QVT Financial LP
|
sell | 425,000 | $26.67 | $11,334,750.00 |
| Dec 17, 2025 |
QVT Financial LP
|
sell | 777,332 | $23.05 | $17,935,594.88 |
| Dec 16, 2025 |
QVT Financial LP
|
sell | 917,282 | $22.93 | $21,129,618.56 |
| Nov 20, 2025 |
Venker Eric
President & Immunovant CEO
|
other | 7,051 | $20.27 | $142,923.77 |
| Nov 19, 2025 |
QVT Financial LP
|
sell | 1,300,000 | $20.25 | $26,304,500.00 |
| Oct 20, 2025 |
MOMTAZEE JAMES C
|
grant | 789 | — | — |
| Oct 20, 2025 |
MOMTAZEE JAMES C
|
other | 158 | $17.74 | $2,802.92 |
| Sep 28, 2025 |
Pulik Richard
CFO
|
other | 2,341 | $15.17 | $35,512.97 |
| Jul 28, 2025 |
Pulik Richard
CFO
|
other | 1,919 | $11.35 | $21,780.65 |
| Jul 17, 2025 |
Epperly Melissa B,
|
grant | 1,609 | — | — |
| Jun 25, 2025 |
Gold Daniel Allen
|
other | 36,756,758 | — | — |
| Jun 25, 2025 |
MANCHESTER KEITH S
|
other | 17,389,525 | — | — |
| Jun 25, 2025 |
QVT Financial LP
|
other | 36,756,758 | — | — |
| Jun 20, 2025 |
Pulik Richard
CFO
|
other | 1,503 | $11.45 | $17,209.35 |
| May 20, 2025 |
Gline Matthew
CEO
|
other | 10,945 | $11.04 | $120,832.80 |
| Apr 17, 2025 |
MOMTAZEE JAMES C
|
grant | 1,379 | — | — |
| Apr 17, 2025 |
MOMTAZEE JAMES C
|
other | 276 | $10.15 | $2,801.40 |
| Apr 17, 2025 |
Epperly Melissa B,
|
grant | 1,847 | — | — |
Dividend History
Yield
0.00%
Payout Ratio
0.00%
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
Key Takeaways
Revenue grew 5.12% annually over 5 years — modest growth
Earnings declined -103.95% over the past year
Debt/Equity of 0.02 — conservative balance sheet
Negative free cash flow of -844.05M
PEG of 0.41 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 16.31%
Growth
Revenue Growth (5Y)
5.12%
Revenue (1Y)-11.19%
Earnings (1Y)-103.95%
FCF Growth (3Y)N/A
Quality
Return on Equity
-3.23%
ROIC-15.72%
Net Margin-591.96%
Op. Margin-3453.32%
Safety
Debt / Equity
0.02
Current Ratio33.47
Interest Coverage0.00
Valuation
P/E Ratio
-113.86
Forward P/EN/A
P/B Ratio4.18
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -11.19% | Revenue Growth (3Y) | -31.14% |
| Earnings Growth (1Y) | -103.95% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 5.12% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 29.05M | Net Income (TTM) | -171.98M |
| ROE | -3.23% | ROA | -3.16% |
| Gross Margin | 96.86% | Operating Margin | -3453.32% |
| Net Margin | -591.96% | Free Cash Flow (TTM) | -844.05M |
| ROIC | -15.72% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.02 | Current Ratio | 33.47 |
| Interest Coverage | 0.00 | ||
| Dividends | |||
| Dividend Yield | 0.00% | Payout Ratio | 0.00% |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -113.86 | Forward P/E | N/A |
| P/B Ratio | 4.18 | P/S Ratio | 674.00 |
| PEG Ratio | 0.41 | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 2084.78 | Fwd Earnings Yield | N/A |
| FCF Yield | -4.31% | ||
| Market Cap | 19.58B | Enterprise Value | 16.97B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 29.05M | 32.71M | 61.28M | 55.29M | 23.80M |
| Net Income | -171.98M | 4.35B | -1.01B | -845.26M | -809.23M |
| EPS (Diluted) | -0.24 | 5.23 | -1.42 | -1.26 | -1.18 |
| Gross Profit | 28.14M | 31.11M | 48.15M | 46.32M | 21.74M |
| Operating Income | -1.00B | 4.50B | -1.18B | -1.35B | -1.07B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 5.44B | 7.22B | 2.39B | 2.59B | 2.69B |
| Total Liabilities | 249.74M | 773.95M | 782.02M | 523.70M | 527.69M |
| Shareholders' Equity | 4.69B | 5.97B | 1.16B | 1.66B | 1.90B |
| Total Debt | 100.17M | 499.75M | 481.40M | 283.89M | 244.98M |
| Cash & Equivalents | 2.72B | 6.54B | 1.68B | 2.06B | 2.13B |
| Current Assets | 5.00B | 6.73B | 1.80B | 2.15B | 2.19B |
| Current Liabilities | 149.41M | 266.76M | 272.45M | 184.37M | 218.96M |